Endo, BioDelivery Pain Drug Meets Primary Endpoint

July 7, 2014 12:36 PM

5 0

A pain drug developed by Endo Pharmaceuticals PLC and BioDelivery Sciences International Inc. met its primary endpoint in a Phase 3 study, the companies said Monday.

Shares of BioDelivery Sciences jumped 22% to $14.60 in premarket trading as the companies prepared to meet with the U.S. Food and Drug Administration over a potential new drug application for BEMA buprenorphine.

Also read: Apple reveals autonomous vehicle ambitions

Read more

To category page

Loading...